A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). (Q51629344)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 May 2015

Language	Label	Description	Also known as
English	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).	scientific article published on 21 May 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

based on heuristic

inferred from title

Igor N. Bondarenko

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Enriqueta Felip

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

S Ramalingam

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

G Goss

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

R Rosell

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

G Schmid-Bindert

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B Zaric

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Z Andric

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D Komov

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

T Ceric

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

F Khuri

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

M Samarzija

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

T Ciuleanu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

V Hirsh

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

T Wehler

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

R Salgia

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

G Shapiro

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Sheldon

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

F Teofilovici

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

V Vukovic

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D Fennell

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

21 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1741-1748

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25997818%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV220

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51629344&oldid=2111277275"